NEW YORK (GenomeWeb News) – Myeloma Health's parent company Signal Genetics said today that Pronto Diagnostics will distribute the Signal Myeloma Prognostic Risk Signature (MyPRS) test in Israel, under an exclusive agreement.
Tel Aviv-based Pronto provides molecular diagnostics-based oncology disease tests and genetic test kits, and it serves as a distributor for Pathwork Diagnostics and Epigenomics.
Signal Genetics' CEO Joe Hernandez said the pact with Pronto "represents our initial entry into the international market with MyPRS and strong interest among both laboratories and physicians outside the United States in providing broader access to this novel technology."
The MyPRS test is performed at Signal Genetics' CLIA-certified lab in Little Rock, Ark.
Financial and other terms of the deal were not disclosed.